Filana Therapeutics, Inc.
FLNA
$1.42
-$0.01-0.70%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 17.47M | 26.59M | 43.27M | 56.99M | 67.07M |
| Gross Profit | -17.47M | -26.59M | -43.27M | -56.99M | -67.07M |
| SG&A Expenses | 29.20M | 30.50M | 33.76M | 39.90M | 82.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.67M | 57.09M | 77.03M | 96.89M | 150.00M |
| Operating Income | -46.67M | -57.09M | -77.03M | -96.89M | -150.00M |
| Income Before Tax | -77.90M | -90.97M | -106.03M | -123.17M | -72.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -77.90 | -90.97 | -106.03 | -123.17 | -72.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.90M | -90.97M | -106.03M | -123.17M | -72.79M |
| EBIT | -46.67M | -57.09M | -77.03M | -96.89M | -150.00M |
| EBITDA | -45.71M | -56.15M | -76.20M | -95.93M | -148.96M |
| EPS Basic | -1.66 | -1.88 | -2.20 | -2.56 | -1.51 |
| Normalized Basic EPS | -0.42 | -0.68 | -0.93 | -1.17 | -1.00 |
| EPS Diluted | -1.66 | -1.89 | -2.20 | -2.56 | -1.51 |
| Normalized Diluted EPS | -0.42 | -0.68 | -0.93 | -1.17 | -1.00 |
| Average Basic Shares Outstanding | 144.92M | 193.19M | 192.98M | 192.65M | 190.54M |
| Average Diluted Shares Outstanding | 193.23M | 193.19M | 192.98M | 192.65M | 190.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |